Cyteir Therapeutics, Inc. (CYT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.7900

-0.1000

(-5.29%)

As of 02:36PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Fast Stochastic

View all chart patterns

Performance Outlook

Previous Close	1.8900
Open	1.8700
Bid	1.7900 x 1100
Ask	1.8000 x 800
Day's Range	1.7800 - 1.9100
52 Week Range	1.5550 - 23.1000
Volume	147,769
Avg. Volume	200,208

Market Cap	63.382M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-1.7610
Earnings Date	Mar 16, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	16.50

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYT

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Cyteir Therapeutics, Inc.
Daily – Vickers Top Buyers & Sellers for 06/25/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Rating
Fair Value
Economic Moat
11 months agoArgus Research

All

Simply Wall St.
Joseph Zakrzewski Is The Independent Investor & Independent Chairman of the Board of Cyteir Therapeutics, Inc. (NASDAQ:CYT) And They Just Picked Up 17% More Shares
Even if it's not a huge purchase, we think it was good to see that Joseph Zakrzewski, the Independent Investor...
- Affinity Bancshares, Inc. (NASDAQ:AFBI) insiders placed bullish bets worth US$1.1m in the last 12 months
  Simply Wall St.
- Insiders in DocuSign, Inc. (NASDAQ:DOCU) are down 27% on their US$12m purchase despite recent gains
  Simply Wall St.
Business Wire
Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational Highlights
LEXINGTON, Mass., May 05, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent operational highlights.
Business Wire
Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare Conference
LEXINGTON, Mass., May 04, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Andrew Gengos, Chief Business Officer and Judd Englert, MD, PhD, Senior Vice President Clinical Research & Development will participate in a fireside chat at the 2022 Bank of America Healthcare Conference. The meeting is being held in person in Las Vegas on Wednesday, May 11, 2022 at 4:2